Zai Lab (ZLAB) said Monday that a phase 3 clinical trial evaluating first-line bemarituzumab plus chemotherapy for the treatment of gastric cancer met its primary endpoint of overall survival at an interim analysis.
The biopharmaceutical company said the treatment combination demonstrated a "statistically significant and clinically meaningful" improvement in overall survival compared with placebo plus chemotherapy.
Zai Lab also said that a phase 3 trial of bemarituzumab plus chemotherapy and nivolumab is ongoing and that data readout is expected in H2.
Shares of Zai Lab were up 2.1% in recent early trading.
Price: 35.46, Change: +0.71, Percent Change: +2.06
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。